$0.01
(0.94%)
0.82%
Add to watchlist
Create an alert
Stocks and Shares ISAFate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Company Information
About this company
Key people
Bahram Valamehr
President, Chief Executive Officer, Director
Kamal Adawi
Chief Financial Officer
Cindy R. Tahl
Chief Legal and Compliance Officer, Corporate Secretary
William H. Rastetter
Independent Chairman of the Board
Matthew C. Abernethy
Independent Director
Shefali Agarwal
Independent Director
Robert S. Epstein
Independent Director
Karin Jooss
Independent Director
Click to see more
Key facts
- Shares in issue115.35m
- EPICFATE
- ISINUS31189P1021
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$128.04m
- Employees181
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.